# EDGAR Filing Document

**Accession Number:** 0001713863
**File Stem:** 0001213900-26-067083
**Filing Date:** 2026-6
**Character Count:** 11110
**Document Hash:** 7a3e25978ed2c870411945e4e5c01875
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-067083.hdr.sgml**: 20260610

**ACCESSION NUMBER**: 0001213900-26-067083

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20260610

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260610

**DATE AS OF CHANGE**: 20260610

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Rafael Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001713863
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 822296593
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0731

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38411
- **FILM NUMBER:** 261078234

**BUSINESS ADDRESS:**
- **STREET 1:** 520 BROAD STREET
- **CITY:** NEWARK
- **STATE:** NJ
- **ZIP:** 07120
- **BUSINESS PHONE:** 212-658-1450

**MAIL ADDRESS:**
- **STREET 1:** 520 BROAD STREET
- **CITY:** NEWARK
- **STATE:** NJ
- **ZIP:** 07120

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934** 

Date of Report (Date of earliest event reported): June 10, 2026

**RAFAEL HOLDINGS, INC.**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-38411** | **82-2296593** |
| **(State or other jurisdiction<br> of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br> Identification No.)** |

---

---

| | |
|:---|:---|
| **520 Broad Street<br> Newark, New Jersey** | **07102** |
| **(Address of principal executive offices)** | **(Zip Code)** |

---

Registrant's telephone number, including area code: 212 658-1450

**Not Applicable** 

**(Former name or former address, if changed since last report.)** 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b)-2 of the Exchange Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol** | **Name of each exchange on which registered** |
| Class B common stock, par value $0.01 per share | RFL | New York Stock Exchange |

---

**Item 7.01. Regulation FD**

On June 10, 2026, Rafael Holdings, Inc. (the "Company") distributed over a wire service and posted the attached press release (the "Release") to the investors page of the Company's website (<u>www.rafaelholdings.com</u>) announcing that the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC*™* study evaluating Trappsol<sup>®</sup> Cyclo™ for the treatment of Niemann-Pick Disease Type C. In addition, the Company announced that Topline data from the main study cohort is expected to be announced in the second half of 2026.

A copy of the Release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The Company is furnishing the information contained in this Report, including Exhibit 99.1, pursuant to Item 2.02 of Form 8-K promulgated by the Securities and Exchange Commission (the "SEC"). This information shall not be deemed to be "filed" with the SEC or incorporated by reference into any other filing with the SEC unless otherwise expressly stated in such filing. In addition, this Report and the press release contain statements intended as "forward-looking statements" that are subject to the cautionary statements about forward-looking statements set forth in the press release.

**Item 8.01. Other Events.**

The information contained in Item 7.01 above is incorporated herein by reference into this Item 8.01.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit No.** | **Document** |
| 99.1 | [Press Release, dated June 10, 2026.](ea029415101ex99-1.htm) |
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL document. |

---

**SIGNATURES** 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| **RAFAEL HOLDINGS, INC.** | **RAFAEL HOLDINGS, INC.** | **RAFAEL HOLDINGS, INC.** |
| By: | /s/ David Polinsky | /s/ David Polinsky |
|  | Name: | David Polinsky |
|  | Title: | Chief Financial Officer |

---

Dated: June 10, 2026

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **Exhibit Number** | **Document** |
| 99.1 | [Press Release, dated June 10, 2026.](ea029415101ex99-1.htm) |
| 104 | Cover Page Interactive Data File, formatted in Inline XBRL document. |

---

## Exhibit 99.1

**Exhibit 99.1** 

**Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal<br> Phase 3 TransportNPC*™* Study Evaluating Trappsol<sup>®</sup> Cyclo™ for the Treatment of<br> Niemann-Pick Disease Type C**

 ****

*Topline results are expected to be announced in second half of calendar 2026*

 

*The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026*

 

*The company has received acknowledgement from the FDA that our US Expanded Access Program (EAP) can proceed*

 

**NEWARK, NJ –June 10, 2026 (GLOBE NEWSWIRE) -** Rafael Holdings, Inc. (NYSE: RFL) today announced the last patient has completed the final 96-week study visit in the pivotal Phase 3 TransportNPC*™* study evaluating Trappsol<sup>®</sup> Cyclo™ for the treatment of Niemann-Pick Disease Type C (NPC). With 94 patients studied across 27 sites in 13 countries, the TransportNPC™ study is the most comprehensive, controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes of an investigational therapy for NPC. Additionally, 10 patients were enrolled in a single-arm sub-study per the adopted Pediatric Investigational Plan (PIP) treating newborns to 3 years of age. Topline data from the main study cohort is expected to be known and announced in the second half of calendar 2026.

Data presented at WORLDSymposium 2026 from the single arm pediatric sub-study in patients ages zero to three, continues to highlight the potential for Trappsol<sup>®</sup> Cyclo™ as a therapeutic option in NPC with 80% of the sub-study patients' CGI scores showing improvements or remaining stable with no serious adverse events considered to be related to the study drug.

"Reaching the conclusion of the pivotal Phase 3 TransportNPC™ trial is a monumental achievement that belongs, first and foremost, to the patients and families, advocacy organizations, and physicians who stood at the heart of this global effort. Together, we have advanced the clinical understanding of NPC, as well as the lived experience of this devastating disease, as we work to deliver a potentially life changing treatment option for a community with significant unmet need," said Joshua Fine, Chief Operating Officer of Rafael Holdings. "We would also like to recognize the FDA for their long-term continued collaboration, engagement and guidance in advancing this program."

 ****

"Having already completed our pre-NDA meeting with the FDA, we believe we have a clear, and expedited path forward reflective of the urgency and unmet need in NPC and expect to submit our NDA in the second half of 2026. NPC represents a high-unmet-need market, positioning Rafael Holdings to potentially unlock substantial, long-term value for our shareholders as we work toward transitioning Rafael Holdings into a commercial-stage biotechnology company," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.

**About Rafael Holdings, Inc.**

Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol<sup>®</sup> Cyclo, which is being evaluated in clinical trials for the potential treatment of NPC a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.

**Forward Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential, safety, efficacy, and regulatory and clinical progress of our product candidates; plans regarding the further evaluation of clinical data; and the potential of our pipeline, including our internal cancer metabolism research programs. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, those disclosed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended July 31, 2025, and our other filings with the SEC. These factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

**Contact:**

Barbara Ryan

Barbara.ryan@rafaelholdings.com

(203) 274-2825

# # #